Prognostic analysis for suspicious radiologic findings (<i>i</i>.<i>e</i>. SPN, LAP and PE) in patients under TAVI evaluation with complete follow-up data (n = 237 patients).

<p>Prognostic analysis for suspicious radiologic findings (<i>i</i>.<i>e</i>. SPN, LAP and PE) in patients under TAVI evaluation with complete follow-up data (n = 237 patients).</p

Baseline characteristics of patients under TAVI evaluation with complete follow-up data (n = 237 patients).

<p>Baseline characteristics of patients under TAVI evaluation with complete follow-up data (n = 237 patients).</p

Diagnostic strategies for incidentally discovered solitary pulmonary nodules (adapted from: Gould et al. 2013).

<p>Diagnostic strategies for incidentally discovered solitary pulmonary nodules (adapted from: Gould et al. 2013).</p

Prognostic impact of left ventricular ejection fraction (LVEF) in the full study collective (p = 0.004).

<p>Overall survival of those patients with a LVEF ≥ 45% was increased compared to those patients with a LVEF < 45%.</p

The incidence of incidentally discovered SPN (cases on chest computer tomographies) and the number of diagnosed lung cancer cases.

<p>The incidence of incidentally discovered SPN (cases on chest computer tomographies) and the number of diagnosed lung cancer cases.</p

Prognostic impact of solitary pulmonary nodules (SPN), lymphadenopathy (LAP) and pleural effusions (PE) in patients under evaluation for TAVI (n = 237 patients).

<p>Kaplan Meier charts are given for SPN ≥ 5mm (<b>A</b>), for SPN > 8mm (<b>B</b>), for LAP (<b>C</b>) and for PE (<b>D</b>).</p

Correlations of clinical and respiratory parameters with suspicious radiologic findings (<i>i</i>.<i>e</i>. SPN, LAP and PE) for patients under TAVI evaluation with complete follow-up data (n = 237 patients).

<p>Correlations of clinical and respiratory parameters with suspicious radiologic findings (<i>i</i>.<i>e</i>. SPN, LAP and PE) for patients under TAVI evaluation with complete follow-up data (n = 237 patients).</p

Overall survival: Explanatory prognostic factors in a Cox proportional Hazards model for the selected study collective.

<p>Included variables: sex (male (ref.) <i>vs</i>. female), age (< 80 years (ref.) <i>vs</i>. ≥ 80 years), LVEF (as a continuous variable), LVEF (LVEF < 45% (ref.) <i>vs</i>. ≥ 45%); previous malignancy (no previous (ref.) malignancy <i>vs</i>. previous malignancy); SPN (no SPN (ref.) <i>vs</i>. SPN ≥ 5 mm and all others (ref.) <i>vs</i>. SPN > 8 mm), lymphadenopathy (no lymphadenopathy (ref.) <i>vs</i>. lymphadenopathy) and pleural effusions (no pleural effusions (ref.) <i>vs</i>. pleural effusions).</p